Over images of laboratory work and equipment, a voiceover explains how the introduction of a new pharmaceutical item onto the market takes much time and effort and now it normally takes years for the process to be complete. She then goes on to talk about how in September 1986 a double blind clinical study to evaluate the drug Retrovir was stopped because it was obvious it helped in stopping mortality in patients. Production of the drug became a priority for Wellcome. Barry Alcock, in charge of Primary Manufacturing at the Dartford plant, describes how the plant was adapted to cope with the new product. Dave Lemon in the Tablet Manufacturing department describes how capsule making equipment was brought in very quickly.